US OptionsDetailed Quotes

VIR241220C10000

Watchlist

0.26
-0.09-25.71%

15min DelayClose Nov 29 13:00 ET

0.26High0.26Low

Vir Biotechnology Stock Discussion

NoNo444

Nov 18 21:10

$Vir Biotechnology (VIR.US)$ The graph looks funny...

Jaguar8

Nov 18 21:06

ADDED NEWS

$Vir Biotechnology (VIR.US)$
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Phase 3 Eclipse Program to Evaluate Tobevibart and Elebsiran

Stock_Drift

Nov 18 20:25

$Vir Biotechnology (VIR.US)$

Trytosaveabit

Nov 18 15:07

Update

$Vir Biotechnology (VIR.US)$ Reuters· just
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta From European Medicines Agency

Stock_Drift

Nov 15 10:27

$Vir Biotechnology (VIR.US)$

QMengColdJoke

Sep 12 10:43

Very displeased cfo pick

$Vir Biotechnology (VIR.US)$ now you wany to sell company. But f you we have 10 dollar per share in equity and that is in cash. Cutting edge science, at least worth 10 dollar. You want to sell right now for how much? 10 dollar? I would sue you if you sell company below 20 dollar.
Firstly of first you need to pump to 20

Trytosaveabit

Sep 9 15:10

Update

$Vir Biotechnology (VIR.US)$ $Sanofi (SNY.US)$ Reuters· 4 mins ago
Vir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell Engagers

QMengColdJoke

Aug 1 17:05

So no more HIV no more covid?

$Vir Biotechnology (VIR.US)$ Good news is my position in GILD is safe. Sick but hell if you boost price to 20, I’ll love to leave. Oncology is crowded path, bad idea.
your own platform is most valuable and made 2 Billion for the company. You just let people go…

Trytosaveabit

Jun 26 07:17

News

$Vir Biotechnology (VIR.US)$ Vir Biotechnology Receives FDA Ind Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection

Trytosaveabit

Jun 5 04:45

Update

$Vir Biotechnology (VIR.US)$ Vir Biotechnology Announced New Preliminary Data From Phase 2 SOLSTICE Hepatitis Delta Trial, Showing Tobevibart Alone Or Combined With Elebsiran Was Generally Well Tolerated And Patients Achieved High Virologic Response And ALT Normalization

No comment yet